ICD carcinoma na renal cell 10

Ciwon ƙwayar ƙwayar cuta (RCC), Mafi yawan nau'in ciwon daji na koda, an rarraba shi ta amfani da Ƙwararren Ƙwararrun Cututtuka na Duniya, Bita na Goma (ICD-10) don dalilai na bincike da ƙididdiga. Fahimtar takamaiman Saukewa: ICD-10 lambobin alaƙa da renal cell carcinoma yana da mahimmanci don ingantaccen rikodi, lissafin kuɗi, da bincike. Wannan labarin yana ba da cikakken bayyani na abin da ya dace Saukewa: ICD-10 lambobin, tsarawa, ganewar asali, da zaɓuɓɓukan magani don renal cell carcinoma.Fahimtar Lambobin ICD-10 don Ciwon Ciwon Ciwon RenalCibiyar Cututtuka ta Duniya, Bita na Goma (Saukewa: ICD-10) tsarin da aka sani a duniya don rarraba cututtuka da yanayin kiwon lafiya. Domin renal cell carcinoma, Ana amfani da takamaiman lambobi don gano nau'in, wuri, da matakin ciwon daji. Madaidaicin coding yana da mahimmanci don ingantaccen tattara bayanai, bayar da rahoto, da kuma biyan kuɗi. Likitoci na iya amfani da lambobin da ke ƙasa a cibiyoyi kamar su Shandong Baofa Cibiyar Nazarin Ciwon daji.Primary Malignancy Lambobin firamare Saukewa: ICD-10 code ga m neoplasms na koda ne C64. Wannan lambar ta ƙunshi rukunoni da yawa waɗanda ke ƙara ƙayyadad da wuri da kuma gefe (ƙoda hagu ko dama): C64.1 - Mummunan neoplasm na koda na dama, ban da ƙashin ƙugu C64.2 - Mummunan neoplasm na koda na hagu, ban da ƙashin ƙashin koda C64.9 - Mummunan neoplasm na koda da ba a bayyana ba, ban da ƙashin ƙashin ƙugu renal cell carcinoma ya metastasized (watsa) zuwa wasu sassa na jiki, ana amfani da ka'idodin malignancy na biyu ban da lambar farko. Misalai sun haɗa da: C79.0 - Na biyu m neoplasm na koda da renal ƙashin ƙugu (ba za a yi amfani da wannan azaman lambar farko ba. renal cell carcinoma.) C79.51 - Na biyu m neoplasm na kashi C78.0 - Na biyu m neoplasm na huhu C77.3 - Na biyu m neoplasm na axilla da na sama reshe Lymph nodeDiagnosis da Staging na Renal Cell Carcinoma Daidaitaccen ganewar asali da tsarawa suna da mahimmanci don tantance tsarin kulawa da ya dace renal cell carcinoma. Ana amfani da waɗannan hanyoyin da yawa: Hanyoyin bincike Gwajin Hoto: Ana amfani da CT scans, MRIs, da ultrasounds don ganin kodan da kuma gano yiwuwar ciwace-ciwacen daji. Biopsy: Ana ɗaukar samfurin nama daga ƙwayar koda kuma a bincika a ƙarƙashin na'urar hangen nesa don tabbatar da kasancewar ƙwayoyin cutar kansa. Gwajin fitsari: Zai iya gano jini ko wasu rashin daidaituwa waɗanda ke nuna matsalolin koda. Gwajin Jini: Tantance aikin koda da kuma lafiyar gabaɗaya.TNM Staging SystemAn yi amfani da tsarin sitiriyo na TNM don rarraba girman renal cell carcinoma: T (Tura): Yana bayyana girma da girman ƙwayar ƙwayar cuta ta farko. N (Nodes): Yana nuna ko ciwon daji ya yadu zuwa nodes na lymph na kusa. M (Metastasis): Yana ƙayyade ko ciwon daji ya daidaita zuwa wurare masu nisa. Matakan TNM sun bambanta daga Stage I (ciwon daji) zuwa Stage IV (cututtukan metastatic). Matakin shine maɓalli mai mahimmanci don tantance tsinkaye da zaɓuɓɓukan jiyya. renal cell carcinoma ya dogara da abubuwa da yawa, ciki har da matakin ciwon daji, gabaɗayan lafiyar majiyyaci, da abubuwan da ake so. Hanyoyi na yau da kullun na magani sun haɗa da: Tiyatar fiɗa daga ƙwayar ƙwayar cuta galibi shine jiyya ta farko don gano wuri renal cell carcinoma. Zaɓuɓɓukan tiyata sun haɗa da: Partanal Nephrectomy: Cire ciwace-ciwacen daji da ƙaramin gefen lafiyayyen nama. Radical Nephrectomy: Cire duka koda, nama da ke kewaye, da nodes na lymph.Magungunan da aka yi niyya da aka yi niyya da ke toshe takamaiman ƙwayoyin cuta da ke cikin haɓakar ƙwayoyin cutar kansa da rayuwa. Wadannan kwayoyi na iya zama tasiri ga ci gaba renal cell carcinoma kuma ana amfani da su sau da yawa lokacin tiyata ba zaɓi ba ne ko bayan tiyata don hana sake dawowa. Misalai sun haɗa da: Sunitinib (Sutent) Pazopanib (Votrient) Axitinib (Inlyta) Cabozantinib (Cabometyx)ImmunotherapyImmunotherapy Magunguna suna haɓaka tsarin garkuwar jiki don yaƙar ƙwayoyin cutar kansa. Wadannan magungunan sun nuna sakamako mai ban sha'awa a cikin maganin ci gaba renal cell carcinoma. Misalai sun haɗa da: Nivolumab (Opdivo) Pembrolizumab (Keytruda) Ipilimumab (Yervoy) Radiation TherapyRadiation far yana amfani da haskoki masu ƙarfi don kashe ƙwayoyin cutar kansa. Wani lokaci ana amfani da shi don yin magani renal cell carcinoma wanda ya yada zuwa wasu sassan jiki ko don kawar da alamun bayyanar cututtuka irin su ciwo.Tsarin Kulawa don ƙananan ciwace-ciwacen daji, jinkirin girma, kulawa mai aiki (kusa da kulawa) na iya zama zaɓi. Wannan ya haɗa da gwaje-gwajen hoto na yau da kullun don lura da haɓakar ƙwayar cuta, tare da fara magani idan ƙari ya fara girma ko haifar da alamun bayyanar. renal cell carcinoma ya bambanta dangane da matakin ciwon daji da sauran dalilai. Farkon mataki renal cell carcinoma yana da babban adadin tsira bayan cirewar tiyata. Duk da haka, ci gaba renal cell carcinoma ya fi ƙalubalanci magani, kuma adadin tsira ya ragu. Ci gaba a cikin maganin da aka yi niyya da kuma rigakafi na rigakafi sun inganta hangen nesa ga marasa lafiya da cututtukan da suka ci gaba. Tebur mai zuwa yana nuna kimanin shekaru 5 na rayuwa don matakai daban-daban. renal cell carcinoma bisa ga bayanai daga Ƙungiyar Ciwon daji ta Amirka: Mataki na 5-Shekaru 5 Matsayin Rayuwa na I 93% Mataki na II 81% Mataki na III 74% Mataki na IV 13% * Yawan rayuwa kiyasi ne kuma yana iya bambanta dangane da yanayin mutum.Kammala fahimtar Saukewa: ICD-10 tsarin coding don renal cell carcinoma, tare da ganewar asali, tsari, da zaɓuɓɓukan magani, yana da mahimmanci ga masu sana'a na kiwon lafiya da marasa lafiya. Ganowa da wuri da magani mai dacewa zai iya inganta sakamako sosai. Don ƙarin bayani game da bincike da jiyya, da fatan za a ziyarci Shandong Baofa Cibiyar Nazarin Ciwon daji game da shafin mu.Rashin yarda: Wannan bayanin don dalilai ne na ilimi kawai kuma bai kamata a yi la'akari da shawarar likita ba. Tuntuɓi ƙwararren ƙwararren kiwon lafiya don duk wata damuwa ta lafiya ko kafin yin kowane yanke shawara mai alaƙa da lafiyar ku ko magani.Sources: Ƙungiyar Cancer ta Amirka: https://www.cancer.org/ Cibiyar Cancer ta Ƙasa: https://www.cancer.gov/